Emergent BioSolutions (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for its Winnipeg, Canada facility ...

First anthrax vaccine developed using recombinant DNA technology- Annual production capacity of up to 10 million doses at GC ...

During this festive season, a seemingly healthy animal that is suddenly dying might look like an enticing source of protein.

Chart does not reflect overnight price.

Chart does not reflect overnight price.